NPPES file of Aug 9, 2026

Understanding Medicare Part D Prescribing Data

What the numbers reveal about prescribing patterns, and what they do not tell you about provider quality.

On this page
  1. What Part D Data Contains
  2. How to Interpret Prescribing Volume
  3. Brand-Name vs. Generic Prescribing
  4. Opioid Prescribing Flags
  5. Limits of the Public Part D File
  6. Using Part D Data Alongside Other Quality Measures

What Part D Data Contains

Each provider row in the Medicare Part D Prescriber Public Use File reports the same set of fields. Here is what each one means, and how to read it.

Field What it measures How to read it
Total claims Prescriptions + refills billed to Part D Tracks patient-panel size and specialty, not quality
Total drug cost Gross cost before rebates Driven by drug mix, not markup by the prescriber
Beneficiaries Distinct Medicare patients served Claims ÷ beneficiaries ≈ scripts per patient
Brand vs. generic Share of claims for brand-name drugs National average ≈ 10–15%; higher is normal in specialty care
Opioid flags Opioid claims, cost, and long-acting flag Expected to be high for pain, oncology, hospice

For every provider who wrote at least 11 prescriptions under Medicare Part D, the dataset includes their NPI, name, specialty, state, total claims, total drug costs, total days' supply, number of beneficiaries, brand-name claims, generic claims, and opioid prescribing flags.

PlainDoctor integrates this data directly into every provider profile. When you look up a doctor, you can see their total Medicare Part D claims, drug costs, beneficiary count, brand-vs-generic ratio, and top prescribed medications. This data reflects the 2024 calendar year, the most recent release available.

How to Interpret Prescribing Volume

Prescribing volume varies enormously by specialty and practice setting. A primary care physician managing 2,000 Medicare patients may write 15,000 claims per year. A psychiatrist managing medication regimens for 500 patients may write similar numbers. A surgeon who mostly performs procedures may write fewer than 200 claims.

Comparing prescribing volumes across specialties is therefore misleading. The useful comparison is within the same specialty: how does this cardiologist's prescribing pattern compare to other cardiologists in the same state? PlainDoctor shows specialty-level prescribing rankings to enable this comparison. Compare providers within the same specialty using the specialty directory.

Most large specialties barely touch Medicare Part D: the 12 largest, and the share of their NPIs in the prescriber file

Source: CMS NPPES, file of Aug 9, 2026; CMS Medicare Part D Prescribers by Provider, 2024 (data.cms.gov).

Brand-Name vs. Generic Prescribing

Generic drugs are chemically identical to their brand-name counterparts and are approved by the FDA through an Abbreviated New Drug Application (ANDA). They cost 80–85% less on average. When a generic equivalent exists, prescribing it instead of the brand-name version saves money for both the patient and Medicare without affecting treatment efficacy.

A provider's brand-name prescribing percentage is one of the few quality-adjacent metrics available in the data. The national average brand-name rate is roughly 10–15%. Providers with significantly higher brand-name percentages may be prescribing medications that lack generic alternatives (common in oncology and specialty care), treating conditions where specific brand formulations are medically necessary, or not considering cost-effective generic alternatives.

Context matters: a rheumatologist prescribing biologic drugs for autoimmune conditions will naturally show a high brand-name percentage because most biologics have no generic equivalents. This is not poor practice, it reflects the treatment landscape for that specialty.

Brand-name share of Part D claims: the highest and lowest specialties

Source: CMS Medicare Part D Prescribers by Provider, 2024, brand-name claims as a share of all claims, by the prescriber's primary specialty.

The specialty breakdown above shows individual prescribing patterns, but the dataset-wide totals reveal a bigger structural asymmetry: across all 1,416,883 providers in the 2024 Part D dataset, generic drugs account for roughly 84% of every claim filed, yet brand-name drugs still account for roughly 72% of the $288.4 billion in total Part D drug spending. In other words, the vast majority of prescriptions are generic, but a comparatively small share of brand-name prescriptions drives most of the dollar cost, the volume-vs-cost gap that policy discussions about Part D spending are usually about, not the number of pills dispensed.

Opioid Prescribing Flags

The Part D dataset includes specific opioid prescribing indicators: total opioid claims, total opioid drug cost, number of opioid beneficiaries, and a long-acting opioid flag. CMS added these indicators to increase transparency around opioid prescribing patterns following the opioid epidemic.

Opioid prescribing data requires careful interpretation. Pain management specialists, oncologists, and hospice providers prescribe opioids at higher rates as a normal part of their clinical practice. A high opioid claim count from a pain management specialist is expected. A similarly high count from a general practitioner may warrant closer examination, but even then, it may reflect a patient population with high chronic pain prevalence.

Limits of the Public Part D File

CMS publishes this file with several material limits on what the reported fields establish:

  • Medicare only: Part D data covers only Medicare beneficiaries (primarily people aged 65+ and those with disabilities). It says nothing about a provider's prescribing for commercially insured or uninsured patients, who may represent the majority of their practice.
  • No clinical context: The data shows what was prescribed but not why. A provider who appears to prescribe expensive brand-name drugs may be treating patients who failed cheaper alternatives, something the data cannot capture.
  • No outcomes: Prescribing data does not indicate whether prescriptions led to good patient outcomes. A provider who prescribes fewer drugs is not necessarily better than one who prescribes more.
  • Privacy suppression: Drugs prescribed to fewer than 11 beneficiaries are suppressed, which means the dataset underrepresents low-volume prescriptions and controlled substances with small patient populations.

Using Part D Data Alongside Other Quality Measures

For a fuller picture of provider quality, use Part D prescribing data alongside CMS MIPS (Merit-based Incentive Payment System) scores, which measure quality, cost, improvement activities, and promoting interoperability. PlainDoctor shows MIPS scores when available on individual provider profiles. Together, prescribing patterns and MIPS scores provide two complementary views: what a provider prescribes and how well their overall practice performs on CMS quality measures.

Browse providers by state or search by name in the provider directory to see both prescribing data and quality scores.

Frequently Asked Questions

What is Medicare Part D prescribing data?

Medicare Part D prescribing data is a public dataset released annually by CMS that shows every prescription drug claim submitted under Medicare Part D by individual healthcare providers. It includes the provider's name, NPI number, drug names, total claims, total drug cost, number of beneficiaries, and whether the prescriptions were brand-name or generic.

Does high prescribing volume indicate a problem?

Not necessarily. High prescribing volume typically reflects a large patient panel, a specialty that requires intensive medication management (such as oncology or psychiatry), or a provider who serves a high proportion of Medicare patients. Volume alone is not a quality indicator.

What does the brand vs. generic prescribing ratio mean?

The brand-name prescribing percentage shows what proportion of a provider's claims were for brand-name drugs versus generics. A higher generic rate generally indicates cost-conscious prescribing. However, some conditions require brand-name drugs when generics are not available. The national average is roughly 10–15% brand-name.

Why are some providers' prescribing details suppressed?

CMS suppresses prescribing details when a provider has fewer than 11 beneficiaries for a specific drug, to protect patient privacy. This is common for providers with small Medicare patient panels or who prescribe controlled substances to a small number of patients.

Next steps

  • Find a prescriber

    Look up your prescriber's Part D profile: most-prescribed drugs, totals and how they compare within the specialty.

  • Prescriber rankings

    See where prescribing concentrates nationally in the top-100 tables.

  • Claims-data guide

    Part D covers Medicare prescriptions only; the claims-data guide explains the rest.

Sources: Centers for Medicare & Medicaid Services, Medicare Part D Prescribers, by Provider and Drug; CMS, Quality Payment Program (MIPS).